Send to

Choose Destination
Diabetes Educ. 2010 May-Jun;36(3):457-64. doi: 10.1177/0145721710363619. Epub 2010 Mar 26.

Management of the metabolic syndrome in patients with human immunodeficiency virus.

Author information

The Nursing and Patient Care Services, Clinical Center, National Institutes of Health, Bethesda, Maryland (Ms Feigenbaum)
The Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, United States Public Health Service, Rockville, Maryland (Ms Longstaff)


Patients with human immunodeficiency virus (HIV) are an increasing subpopulation of patients seen in endocrine/diabetes clinics. This article explores evidence-based treatment recommendations for patients with metabolic syndrome who are also positive for HIV. Patients infected with HIV may manifest metabolic abnormalities. They often present with low high-density lipoprotein (HDL-C), hypertension, visceral adiposity, and insulin resistance, among other symptoms consistent with features of the metabolic syndrome. The etiologies of the metabolic abnormalities are not completely understood. The role of highly active antiretroviral therapy (HAART) and the separate effect of HIV on patients who are surviving longer may contribute to the increased incidence of the development of the metabolic syndrome. The role of the health care team is to provide patient education to patients with HIV concerning lifestyle modification in order to prevent complications related to the metabolic syndrome.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center